Active substances produced in the Republic of Korea are in line with EU standards says the commission. To guarantee their quality active substances manufactured in third countries like the Republic of Korea, and intended for human medicines placed on the EU market, have to be produced in an EU equivalent regulatory System including rules for good manufacturing practices (GMP).